UK markets closed

AnaptysBio, Inc. (0HFQ.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
86.95+51.98 (+148.64%)
At close: 3:26PM GMT
Full screen
Previous close34.97
Open26.00
Bid0.00 x N/A
Ask0.00 x N/A
Day's range26.00 - 26.00
52-week range26.00 - 26.00
Volume50
Avg. volumeN/A
Market capN/A
Beta (5Y monthly)0.13
PE ratio (TTM)N/A
EPS (TTM)-0.73
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Why AnaptysBio Was a Stock Market Star on Friday
    Motley Fool

    Why AnaptysBio Was a Stock Market Star on Friday

    What happened AnaptysBio (NASDAQ: ANAB) closed more than 10% higher on Friday. This followed news that a drug the company partnered on has received a positive opinion from an important multinational health agency.

  • Why AnaptysBio Fell by as Much as 10% Today
    Motley Fool

    Why AnaptysBio Fell by as Much as 10% Today

    On Tuesday, AnaptysBio (NASDAQ: ANAB) traded down nearly 10% at one point, before recovering to end the day 2.5% higher. There wasn't any direct news driving such sentiments; rather, it seems other factors were at play. AnaptysBio is a clinical-stage biotech that concentrates on immunology therapies -- currently a hot area of development in the healthcare world.

  • Why AnaptysBio Trounced the Market on Thursday
    Motley Fool

    Why AnaptysBio Trounced the Market on Thursday

    AnaptysBio (NASDAQ: ANAB) rose by just over 11% on Thursday, as a high-profile bank has become more optimistic on the stock, to put it lightly. J.P. Morgan analyst Anupam Rama upgraded his recommendation on AnaptysBio stock. Rama is basing his enthusiasm on the company's upcoming official data release for its phase 2 clinical trial of imsidolimab.